Both of these therapies become ineffective when prostate cancer recurs in a castration-resistant state and the AR neither depends on androgens nor is antagonized by anti-androgens (i.e. Bicalutamide), and the outcome is usually death [21]. This evidence concerns the gene AR and prostate carcinoma.